Of note, the AR+ HOXB13-negative GRN in the ARhigh/PSMAlow sample showed robust STEAP1 and STEAP2 expression, suggesting that cotargeting of STEAP and PSMA in AR-positive disease may be an effective strategy to achieve broader tumor cell coverage (4) (Fig. 4D). The gene discussed is STEAP2; the disease is neoplasm.